August 15, 2025 7:39am

Maybe it could promote share pricing recovery, portfolio health benefits and increased momentum to spark a wave of positivity your investment can release

BREAKING: July’s retail sales data, released on Friday morning, painted a still-healthy picture for the U.S. consumer. Retail sales rose 0.5% last month, meeting expectations. Retail sales excluding automobiles gained 0.3%, also matching estimates.

Pre-open Signals: 4 Positive Indications

Watch as the release of retail sales data will offer clues as to whether/will Trump's tariffs are impacting consumer spending habits?

News: Precigen (PGEN +$0.985 to $2.84) the FDA has approved PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP) … the first and only FDA-approved therapy for the treatment of adults with RRP. PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen comprising selected regions of human papillomavirus (HPV) types 6 and 11 proteins - the root cause of RRP. PAPZIMEOS is delivered via 4 subcutaneous injections over a 12-week interval.

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

TGIF

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

There are buying opportunities and sell signals, but many names are likely to reverse direction after the open …

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Thursday’s night’s … RegMed Investors (RMi) Closing Bell: Indexes waver as sector shuffled after econs … https://www.regmedinvestors.com/articles/14064

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Friday: The pre-open Dow futures are UP +0.57% or (+258 points), the S&P futures are UP +0.09% or (+6 points) and the Nasdaq futures are DOWN -0.14% or (-33 point)

  • U.S. stock futures were still mixed after retail sales report on Friday, 8/15
  • European markets continued positive in the session,
  • Asia-Pacific markets rose as investors assessed Japan’s GDP and the flurry of Chinese economic data.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -11.01 points or -0.02%, the S&P closed UP +1.96 points or +0.03% while the Nasdaq closed DOWN -2.47 points or -0.01%
  • Wednesday: The Dow closed UP +463.66 points or +1.04%, the S&P closed UP +20.82 points or +0.32% while the Nasdaq closed UP +31.236 points or +0.14%
  • Tuesday: The Dow closed UP +483.52 points or +1.10%, the S&P closed UP +72.31 points or +1.13% while the Nasdaq closed UP +296.50 points or +1.39%
  • Monday: The Dow closed DOWN -200.52 points or -0.45%, the S&P closed DOWN -16 points or -0.25% while the Nasdaq closed DOWN -64.62 points or -0.30%
  • Last week, the S&P 500 has gained 2.5%, the Nasdaq has added +3.9% and the Dow has advanced 1.4%.
  • The previous week, the Dow tumbled -2.9%, the S&P 500 dropped -2.4% and the Nasdaq lost -2.2%

Economic Data Docket: import prices, consumer sentiment and retail sales

 

Q3 – August - 6 negative and 4 positive closes

•             July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I’ll pass; …. an escape from this week’s econs and more earnings releases, and the usual ups, downs and just plain uncertainty

Although …

Alnylam Pharmaceuticals (ALNY +$10.21 after Wednesday’s +$2.59 after Tuesday’s -$5.07 after Monday’s -$3.93 with a negative -$1.66 or +0.60% pre-open

CRISPR Therapeutics (CRSP +$1.55 with a positive +$1.32 or +2.24% pre-open

Lenz Therapeutics (LENZ +$1.56 after Wednesday’s +$3.03 after Tuesday’s -$2.44 after Monday’s +$4.09 with a positive +$0.89 or +2.18% pre-open

uniQure NV (QURE +$1.18 with a positive +$0.42 or +2.66% pre-open

 

The BOTTOM LINE: Key word today – EXPECTATION … which took a hit on Thursday, however, after a much hotter-than-expected wholesale inflation report.

Cell and gene therapy equities initially fell but managed to recover most of their losses, closing barely positive <advance/decline line of 18/17.

 

August: understand the “flow” …

  • 8/14 – Thursday closed positive with 18 positive, 17 negative and 0 flat
  • 8/13 – Wednesday closed positive with 32 positive, 2 negative and 1 flat
  • 8/12 - Tuesday closed positive with 28 positive, 6 negative and 1 flat
  • 8/11 – Monday closed negative with 10 positive, 25 negative and 0 flat
  • 8/8 – Friday closed negative with 11 positive, 23 negative and 1 flat
  • 8/7 – Thursday closed negative with 9 positive, 24 negative and 2 flats
  • 8/6 – Wednesday closed negative with 11 positive, 22 negative and 2 flats
  • 8/5 – Tuesday closed negative with 15 positive, 19 negative and 1 flat
  • 8/4 – Monday closed positive with 27 positive, 8 negative and 0 flats
  • 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats

 

Earnings are still the highlight of the week: Meeting earnings expectation and/or missing consensus will deem share pricing outcomes.

  • Earnings:  4 net incomes and 25 net losses of 29 releases to date

 

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • As always, I brace myself for earnings associated with share pricing volatility, some economics and tariff developments and their effects?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.